REGISTRY OF TREATMENT PATTERNS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) WITH PROGRESSION DURING OR AFTER DOCETAXEL-BASED REGIMEN

REGISTRY OF TREATMENT PATTERNS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) WITH PROGRESSION DURING OR AFTER DOCETAXEL-BASED REGIMEN - PROXIMA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007729

Enrollment

900

Registered

2012-04-12

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic castration registant prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: -Men &#8805;18 years of age -Prostate adenocarcinoma -mCRPC progressing during or after docetaxel-based chemotherapy -Patient who have given their written consent

Exclusion criteria

Exclusion criteria: -Patients having already started a new treatment line for mCRPC -Participation in a clinical study in which study treatment is blinded

Design outcomes

Primary

Measure	Time frame
Sequence of treatment lines observed during a period of 12 months in patients who received docetaxel-based regimen and have disease progression	—

Secondary

Measure	Time frame
-Physician criteria for therapeutic decision -Characteristics of patients who receive a further treatment after docetaxel-based regimen -Tumor response during docetaxel-based regimen -Tumor reponse for subsequent treatments -Type of disease progression during docetaxel based-regimen -Type of disease progression during subsequent lines of treatment -Sequence of treatments other than chemotherapy and hormonotherapy -Progression-free survival and overall survival with different treatment modalities -QOL ( EQ-5D; FACT-P)	—

Measure

Time frame

-Physician criteria for therapeutic decision -Characteristics of patients who receive a further treatment after docetaxel-based regimen -Tumor response during docetaxel-based regimen -Tumor reponse for subsequent treatments -Type of disease progression during docetaxel based-regimen -Type of disease progression during subsequent lines of treatment -Sequence of treatments other than chemotherapy and hormonotherapy -Progression-free survival and overall survival with different treatment modalities -QOL ( EQ-5D; FACT-P)

—

Countries

Japan,Asia(except Japan),South America,Europe,Africa

Contacts

Public ContactPROXIMA office

Sanofi K.K. CSU

03-6301-3730

Outcome results